Turn recording back on
Therapeutic targets in systemic sclerosis.
Denton CP.
Arthritis Res Ther. 2007;9 Suppl 2:S6. Review.
PMID: 17767744 [PubMed - indexed for MEDLINE]
Related Articles Free article in PMC
Targeted therapy comes of age in scleroderma.
Denton CP, Black CM.
Trends Immunol. 2005 Nov;26(11):596-602. Epub 2005 Sep 15. Review.
PMID: 16168710 [PubMed - indexed for MEDLINE]
Related Articles
Mechanisms and consequences of fibrosis in systemic sclerosis.
Denton CP, Black CM, Abraham DJ.
Nat Clin Pract Rheumatol. 2006 Mar;2(3):134-44. Review.
PMID: 16932673 [PubMed - indexed for MEDLINE]
Pulmonary arterial hypertension in systemic sclerosis: clinical manifestations, pathophysiology, evaluation, and management.
Ramirez A, Varga J.
Treat Respir Med. 2004;3(6):339-52. Review.
PMID: 15658881 [PubMed - indexed for MEDLINE]
Management of systemic sclerosis: the art and science.
Stone JH, Wigley FM.
Semin Cutan Med Surg. 1998 Mar;17(1):55-64. Review.
PMID: 9512108 [PubMed - indexed for MEDLINE]
Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis.
Sfikakis PP, Papamichael C, Stamatelopoulos KS, Tousoulis D, Fragiadaki KG, Katsichti P, Stefanadis C, Mavrikakis M.
Arthritis Rheum. 2007 Jun;56(6):1985-93.
PMID: 17530638 [PubMed - indexed for MEDLINE]
Targeting fibrosis in systemic sclerosis.
Lafyatis R.
Endocr Metab Immune Disord Drug Targets. 2006 Dec;6(4):395-400. Review.
PMID: 17214585 [PubMed - indexed for MEDLINE]
[Bosentan for treatment of active digital ulcers in patients with systemic sclerosis]
Launay D, Diot E, Pasquier E, Mouthon L, Boullanger N, Fain O, Jego P, Carpentier P, Hatron PY, Hachulla E.
Presse Med. 2006 Apr;35(4 Pt 1):587-92. French.
PMID: 16614599 [PubMed - indexed for MEDLINE]
Bosentan for the treatment of systemic sclerosis-associated pulmonary arterial hypertension, pulmonary fibrosis and digital ulcers.
Jain M, Varga J.
Expert Opin Pharmacother. 2006 Aug;7(11):1487-501. Review.
PMID: 16859432 [PubMed - indexed for MEDLINE]
Therapeutic challenges for systemic sclerosis: facts and future targets.
Cerinic Matucci M, Del Rosso A, Federico P, Livi R, Fiori G, Bartoli F, Blagojevic J, Tempestini A, Pignone A.
Ann N Y Acad Sci. 2007 Sep;1110:448-54.
PMID: 17911460 [PubMed - indexed for MEDLINE]
How does endothelial cell injury start? The role of endothelin in systemic sclerosis.
Abraham D, Distler O.
Arthritis Res Ther. 2007;9 Suppl 2:S2. Review.
PMID: 17767740 [PubMed - indexed for MEDLINE]
Molecular pathways as novel therapeutic targets in systemic sclerosis.
Trojanowska M, Varga J.
Curr Opin Rheumatol. 2007 Nov;19(6):568-73. Review.
PMID: 17917537 [PubMed - indexed for MEDLINE]
Cytokine directed therapy in scleroderma: rationale, current status, and the future.
Simms RW, Korn JH.
Curr Opin Rheumatol. 2002 Nov;14(6):717-22. Review.
PMID: 12410097 [PubMed - indexed for MEDLINE]
Autoimmunity in systemic sclerosis: current concepts.
Boin F, Rosen A.
Curr Rheumatol Rep. 2007 May;9(2):165-72. Review.
PMID: 17502048 [PubMed - indexed for MEDLINE]
Cytokines as therapeutic targets for the gastrointestinal manifestations of scleroderma.
Raoul JM, Verma M, Tan E, Peterson TC.
Can J Gastroenterol. 2004 Jan;18(1):22-4. Review.
PMID: 14760427 [PubMed - indexed for MEDLINE]
Scleroderma. Clinical problems. The lungs.
Silver RM.
Rheum Dis Clin North Am. 1996 Nov;22(4):825-40. Review.
PMID: 8923598 [PubMed - indexed for MEDLINE]
[Pathogenic mechanisms in systemic sclerosis and their therapeutical consequences. Part 2: treatment]
Zuber JP, Chizzolini C, Leimgruber A, Bart PA, Spertini F.
Rev Med Suisse. 2006 Apr 19;2(62):1058, 1060-6. Review. French.
PMID: 16711151 [PubMed - indexed for MEDLINE]
Pulmonary involvement in systemic sclerosis.
Shahin AA.
Treat Respir Med. 2006;5(6):429-36.
PMID: 17154672 [PubMed - in process]
Recent advances on pathogenesis and therapies in systemic sclerosis.
Yazawa N, Fujimoto M, Tamaki K.
Clin Rev Allergy Immunol. 2007 Oct;33(1-2):107-12. Review.
PMID: 18064573 [PubMed - indexed for MEDLINE]
Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6.
Merkel PA, Clements PJ, Reveille JD, Suarez-Almazor ME, Valentini G, Furst DE; OMERACT 6.
J Rheumatol. 2003 Jul;30(7):1630-47. Review.
PMID: 12858472 [PubMed - indexed for MEDLINE]